Using the circulating proteome to assess type I interferon activity in systemic lupus erythematosus.

导出 LinkOut

翻译打印收藏纠错

作者： Michael A,Smith ^[1] ; Chia-Chien,Chiang ^[1] ; Kamelia,Zerrouki ^[1] ; Saifur,Rahman ^[1] ; Wendy I,White ^[1] ; Katie,Streicher ^[1] ; William A,Rees ^[1] ; Adam,Schiffenbauer ^[2] ; Lisa G,Rider ^[2] ; Frederick W,Miller ^[2] ; Zerai,Manna ^[3] ; Sarfaraz,Hasni ^[3] ; Mariana J,Kaplan ^[4] ; Richard,Siegel ^[5] ; Dominic,Sinibaldi ^[6] ; Miguel A,Sanjuan ^[1] ; Kerry A,Casey ^[7]

作者单位： AstraZeneca, Gaithersburg, MD, USA. ^[1] Environmental Autoimmunity Group, Clinical Research Branch, National Institute of Environmental Health Sciences, National Institutes of Health, Bethesda, MD, USA. ^[2] Lupus Clinical Research Program, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, USA. ^[3] Systemic Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Disease, National Institutes of Health, Bethesda, MD, USA. ^[4] Immunoregulation Section, Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, USA. ^[5] AstraZeneca, Gaithersburg, MD, USA. dominic.sinibaldi@astrazeneca.com. ^[6] AstraZeneca, Gaithersburg, MD, USA. kerry.casey@bms.com. ^[7]